## **BME** Distinguished Seminar

Friday, November 18, 2016 4 pm in PHO 206 Followed by reception in PHO 1<sup>st</sup> floor atrium and lounge

David Cook, Ph.D.
Seres Therapeutics, Inc.
Cambridge, MA

"The Human Microbiome: A Target for Ecobiotic Drugs"

Next-generation sequencing has enabled a genomic description of the human microbiome, the collection of microbes that live on and in us. The microbiome has been associated with many important functions integral to human health, including resistance to infections, education and regulation of the immune system, production of hormones and vitamins, and regulation of metabolic status. Recent reports even associate the microbiome with mood, depression and neurologic disorders. Given these many links to human health, the microbiome will be a target for biomedical interventions. This presentation will describe some of the efforts at Seres Therapeutics, a leading microbiome drug developer, to define a new class of therapeutics based on commensal microorganisms derived from the gastrointestinal microbiota.